B cell maturation antigen (BCMA) is a target for various immunotherapies and a biomarker for tumor load in multiple myeloma (MM). We report a case of irreversible BCMA loss in a patient with MM who was enrolled in the KarMMa trial ( NCT03361748 ) and progressed after anti-BCMA CAR T cell therapy. We identified selection of a clone with homozygous deletion of TNFRSF17 (BCMA) as the underlying mechanism of immune escape. Furthermore, we found heterozygous TNFRSF17 loss or monosomy 16 in 37 out of 168 patients with MM, including 28 out of 33 patients with hyperhaploid MM who had not been previously treated with BCMA-targeting therapies, suggesting that heterozygous TNFRSF17 deletion at baseline could theoretically be a risk factor for BCMA loss after immunotherapy.
Description
Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma | Nature Medicine
%0 Journal Article
%1 Da_Vi__2021
%A Vià, Matteo C. Da
%A Dietrich, Oliver
%A Truger, Marietta
%A Arampatzi, Panagiota
%A Duell, Johannes
%A Heidemeier, Anke
%A Zhou, Xiang
%A Danhof, Sophia
%A Kraus, Sabrina
%A Chatterjee, Manik
%A Meggendorfer, Manja
%A Twardziok, Sven
%A Goebeler, Maria-Elisabeth
%A Topp, Max S.
%A Hudecek, Michael
%A Prommersberger, Sabrina
%A Hege, Kristen
%A Kaiser, Shari
%A Fuhr, Viktoria
%A Weinhold, Niels
%A Rosenwald, Andreas
%A Erhard, Florian
%A Haferlach, Claudia
%A Einsele, Hermann
%A Kortüm, K. Martin
%A Saliba, Antoine-Emmanuel
%A Rasche, Leo
%D 2021
%I Springer Science and Business Media LLC
%J Nature Medicine
%K myown
%N 4
%P 616--619
%R 10.1038/s41591-021-01245-5
%T Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma
%U https://doi.org/10.1038%2Fs41591-021-01245-5
%V 27
%X B cell maturation antigen (BCMA) is a target for various immunotherapies and a biomarker for tumor load in multiple myeloma (MM). We report a case of irreversible BCMA loss in a patient with MM who was enrolled in the KarMMa trial ( NCT03361748 ) and progressed after anti-BCMA CAR T cell therapy. We identified selection of a clone with homozygous deletion of TNFRSF17 (BCMA) as the underlying mechanism of immune escape. Furthermore, we found heterozygous TNFRSF17 loss or monosomy 16 in 37 out of 168 patients with MM, including 28 out of 33 patients with hyperhaploid MM who had not been previously treated with BCMA-targeting therapies, suggesting that heterozygous TNFRSF17 deletion at baseline could theoretically be a risk factor for BCMA loss after immunotherapy.
@article{Da_Vi__2021,
abstract = {B cell maturation antigen (BCMA) is a target for various immunotherapies and a biomarker for tumor load in multiple myeloma (MM). We report a case of irreversible BCMA loss in a patient with MM who was enrolled in the KarMMa trial ( NCT03361748 ) and progressed after anti-BCMA CAR T cell therapy. We identified selection of a clone with homozygous deletion of TNFRSF17 (BCMA) as the underlying mechanism of immune escape. Furthermore, we found heterozygous TNFRSF17 loss or monosomy 16 in 37 out of 168 patients with MM, including 28 out of 33 patients with hyperhaploid MM who had not been previously treated with BCMA-targeting therapies, suggesting that heterozygous TNFRSF17 deletion at baseline could theoretically be a risk factor for BCMA loss after immunotherapy. },
added-at = {2021-04-06T17:33:40.000+0200},
author = {Vià, Matteo C. Da and Dietrich, Oliver and Truger, Marietta and Arampatzi, Panagiota and Duell, Johannes and Heidemeier, Anke and Zhou, Xiang and Danhof, Sophia and Kraus, Sabrina and Chatterjee, Manik and Meggendorfer, Manja and Twardziok, Sven and Goebeler, Maria-Elisabeth and Topp, Max S. and Hudecek, Michael and Prommersberger, Sabrina and Hege, Kristen and Kaiser, Shari and Fuhr, Viktoria and Weinhold, Niels and Rosenwald, Andreas and Erhard, Florian and Haferlach, Claudia and Einsele, Hermann and Kortüm, K. Martin and Saliba, Antoine-Emmanuel and Rasche, Leo},
biburl = {https://www.bibsonomy.org/bibtex/2285d08990b1ab003f725f6800dc06757/cusysmed},
day = 22,
description = {Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma | Nature Medicine},
doi = {10.1038/s41591-021-01245-5},
interhash = {9ae0b343617e7d69ac1dc8f8d3f9b639},
intrahash = {285d08990b1ab003f725f6800dc06757},
journal = {Nature Medicine},
keywords = {myown},
month = feb,
number = 4,
pages = {616--619},
publisher = {Springer Science and Business Media LLC},
timestamp = {2024-04-16T17:12:26.000+0200},
title = {Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma},
type = {Publication},
url = {https://doi.org/10.1038%2Fs41591-021-01245-5},
volume = 27,
year = 2021
}